| • |
Association between insulin secretion, insulin sensitivity and type 2 diabetes susceptibility variants identified in genome-wide association studies
Ruchat SM, Elks CE, Loos RJ, et al
Acta Diabetol. 2009;46(3):217-226 |
| • |
Preoperative hypoglycemia in a patient receiving insulin detemir
Olson RP, Bethel MA, Lien L
Anesth Analg. 2009;108(6):1836-1838 |
| • |
DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results
Buse JB, Wolffenbuttel BH, Herman WH, et al
Diabetes Care. 2009;32(6):1007-1013 |
| • |
Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L
Diabetes Care. 2009 Jun 5. [Epub ahead of print] |
| • |
Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD)
McEwen LN, Bilik D, Johnson SL, et al
ACC Abstracts of the 48th Scientific Session. 2009;32(6):971-976 |
| • |
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial
Bunck MC, Diamant M, Cornér A, et al
Diabetes Care. 2009;32(5):762-768 |
| • |
Insulin-dependent actions of pioglitazone in newly diagnosed, drug naïve patients with type 2 diabetes
Kutoh E, Fukushima T.
Endocr J. 2009 Apr 15. [Epub ahead of print] |
| • |
Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai Healthcare Study
Sato KK, Hayashi T, Harita N, Yoneda T, Nakamura Y, Endo G, Kambe H
Diabetes Care. 2009;32(4):644-646 |
| • |
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus
Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJ, Stehouwer CD
Arch Intern Med. 2009;169(6):616-625 |
| • |
Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial.
Raz I, Wilson PW, Strojek K, et al
Diabetes Care. 2009;32(3):381-386 |
| • |
Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes
White NH, Chase HP, Arslanian S, Tamborlane WV for the 4030 Study Group
Diabetes Care. 2009;32(3):387-393 |
| • |
Pioglitazone vs glimepiride: differential effects on vascular endothelial function in patients with type 2 diabetes
Papathanassiou K, Naka KK, Kazakos N, et al
Atherosclerosis. 2008 Dec 6. [Epub ahead of print] |
| • |
One-year treatment with exenatide improves beta-cell function, compared to insulin glargine, in metformin treated type 2 diabetes patients: a randomized, controlled trial
Bunck MC, Diamant M, Cornér A, et al
Diabetes Care. 2009 Feb 5. [Epub ahead of print] |
| • |
Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus
González-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, et al
J Diabetes and Its Complications. 2008 Oct 10. [Epub ahead of print] |
| • |
Sustained Efficacy and Reduced Hypoglycemia during One Year of Treatment with Vildagliptin Added to Insulin in Patients with Type 2 Diabetes Mellitus *.
Fonseca V, Baron M, Shao Q, Dejager S.
Horm Metab Res. 2008 Jun;40(6):427-30. Epub 2008 Mar 11 |
| • |
Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy.
Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S.
Diabetes Care. 2008 Jan;31(1):20-5 |
| • |
Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus.
Chlup R, Zapletalová J, Seckar P, et al
Diabetes Technol Ther. 2007;9:223-231 |
| • |
Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study.
Bailey TS, Zisser HC, Garg SK
Diabetes Technol Ther. 20079:203-210 |
| • |
Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US
Ray JA, Valentine WJ, Roze S, et al
Diabetes, Obesity and Metabolism. 2007;9:103-113 |
| • |
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
Nauck MA, Duran S, Kim D, et al
Diabetologia. 2007;50:259-267 |
| • |
Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies
Hayashi T, Hirano T, Yamamoto T, Ito Y, Adachi M
Metabolism. 2006;55:879-884 |
| • |
A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT Study.
Gerstein HC, Yale JF, Harris SB, et al
Diabet Med. 2006;23:736-742 |
| • |
Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes
Dorkhan M, Magnusson M, Frid A, et al
J Intern Med. 2006;260:125-133 |
| • |
Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome
Derosa G, D'Angelo A, Ragonesi PD, et al
J Clin Pharm Ther. 2006;31:375-383 |
| • |
An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin
Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M
Diabetes Care. 2006;29:1818-1825 |
| • |
The hyperglycemia: intensive insulin infusion in infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction
Cheung NW, Wong VW, McLean M
Diabetes Care. 2006;29:765-770 |
| • |
Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study
Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al
Diabetologia. 2006;49:442-451 |
| • |
Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial
Rosenstock J, Zinman B, Murphy LJ, et al
Ann Intern Med. 2005;143:549-558 |
| • |
Efficacy of Inhaled Insulin in Patients With Type 2 Diabetes not Controlled With Diet and Exercise: A 12-week, randomized, comparative trial
Defronzo RA, Bergenstal RM, Cefalu WT, et al
Diabetes Care. 2005;28:1922-1928 |
| • |
Frequency, severity, and morbidity of hypoglycemia occurring in the workplace in people with insulin-treated diabetes
Leckie AM, Graham MK, Grant JB, Ritchie PJ, Frier BM
Diabetes Care. 2005;28:1333-1338 |
| • |
Insulin glulisine provides improved glycemic control in patients with type 2 diabetes
Dailey G, Rosenstock J, Moses RG, Ways K
Diabetes Care. 2004;27:2363-2368 |
| • |
Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes
Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N
Health Technol Assess. 2004;8:1-186 |
| • |
Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus
Sidhu JS, Cowan D, Kaski JC
Am J Cardiol.. 2004;94:151-156 |
| • |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus
Esposito K, Giugliano D, Nappo F, Marfella R
Circulation. 2004;110:214-219 |
| • |
Implementation of a Safe and Effective Insulin Infusion Protocol in a Medical Intensive Care Unit
Goldberg PA, MD, Siegel MD, MD, Sherwin RS, MD, et al
Diabetes Care. 2004;27:461-467 |
| • |
Beneficial Effects of Insulin Versus Sulphonylurea on Insulin Secretion and Metabolic Control in Recently Diagnosed Type 2 Diabetic Patients
Alvarsson M, Sundkvist G, Lager I, et al
Diabetes Care. 2003;26:2231-2237 |
| • |
Factors Affecting Progression of Renal Failure in Patients With Type 2 Diabetes
Ueda H, Ishimura E, Shoji T, et al
Diabetes Care. 2003;26:1530-1534 |
| • |
Insulin Therapy Improves Glycemic Control Without an Adverse Influence on Quality of Life
|
| • |
In Patients With Diabetes, Use of Healthcare Resources Is Higher in Those Treated With Insulin Than in Those Treated With Oral Agents and Diet
|
| • |
Insulin Therapy Associated With Lower Quality of Life in Type 2 Diabetes Mellitus
|
| • |
Metabolic and Immunologic Effects of Insulin Lispro in Gestational Diabetes
|
